AGEN vs. NVAX, BCRX, ALVO, VYGR, AURA, HUMA, SOPH, FATE, CHRS, and FENC
Should you be buying Agenus stock or one of its competitors? The main competitors of Agenus include Novavax (NVAX), BioCryst Pharmaceuticals (BCRX), Alvotech (ALVO), Voyager Therapeutics (VYGR), Aura Biosciences (AURA), Humacyte (HUMA), SOPHiA GENETICS (SOPH), Fate Therapeutics (FATE), Coherus BioSciences (CHRS), and Fennec Pharmaceuticals (FENC). These companies are all part of the "biological products, except diagnostic" industry.
Novavax (NASDAQ:NVAX) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, community ranking, valuation, earnings, dividends and media sentiment.
Novavax has a net margin of -52.29% compared to Novavax's net margin of -280.44%.
In the previous week, Novavax and Novavax both had 2 articles in the media. Agenus' average media sentiment score of 0.21 beat Novavax's score of -0.58 indicating that Novavax is being referred to more favorably in the media.
Novavax has a beta of 1.73, indicating that its stock price is 73% more volatile than the S&P 500. Comparatively, Agenus has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500.
Agenus has lower revenue, but higher earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.
Novavax currently has a consensus price target of $25.00, indicating a potential upside of 357.88%. Agenus has a consensus price target of $8.10, indicating a potential upside of 1,126.72%. Given Novavax's stronger consensus rating and higher possible upside, analysts clearly believe Agenus is more favorable than Novavax.
Novavax received 379 more outperform votes than Agenus when rated by MarketBeat users. Likewise, 74.34% of users gave Novavax an outperform vote while only 70.38% of users gave Agenus an outperform vote.
71.5% of Novavax shares are owned by institutional investors. Comparatively, 55.4% of Agenus shares are owned by institutional investors. 0.9% of Novavax shares are owned by company insiders. Comparatively, 4.8% of Agenus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Novavax and Agenus tied by winning 8 of the 16 factors compared between the two stocks.
Get Agenus News Delivered to You Automatically
Sign up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
